RxSight: Disrupting The Premium Intraocular Lens Market

Mar. 28, 2023 12:16 PM ETRxSight, Inc. (RXST) StockRXST17 Comments

Summary

  • RxSight's innovative product, the Light Adjustable Lens, was launched in 2020 and managed to capture a 5% market share by late 2022.
  • The market is expected to double in five years and international expansion is another significant long-term opportunity.
  • RxSight is still generating losses, but gross margins are improving and the company is well-funded to continue to execute.
  • RxSight looks well-positioned to disrupt the premium intraocular lens market.
  • Looking for more investing ideas like this one? Get them exclusively at Growth Stock Forum. Learn More »

Focused, serious medical scientists analyzing research scans on a computer, working late in the laboratory. Lab workers examine and talk about results from a checkup while working overtime

Sean Anthony Eddy

RxSight's (NASDAQ:RXST) innovative product - the RxSight Light Adjustable Lens ('LAL') system was launched in the United States in 2020 and it was able to capture 5% of the premium intraocular lens ('IOL') market by the end of 2022. Revenues in 2022 grew

I publish my best ideas and top coverage on the Growth Stock Forum. If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button. And to go deeper, sign up for a free trial to Growth Stock Forum.

This article was written by

9.22K Followers

ONeil Trader is a former stockbroker turned full-time independent investor. He focuses on finding growth and biotech stocks with significant growth potential and calculates ideas in large part based on best risk-adjusted returns.

He leads the investing group Growth Stock Forum which features: a model portfolio of 15-20 names updated regularly, a top picks list of up to 10 stocks that are expected to perform well in the current calendar year, trading ideas that target both short-term and medium-term moves, and chat with community dialogue and for questions. Learn More.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of RXST either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article reflects the author's opinion and should not be regarded as a buy or sell recommendation or investment advice in any way.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About RXST Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on RXST

Related Stocks

SymbolLast Price% Chg
RXST
--